Determination of Drug-to-Antibody Ratio for Antibody-Drug Conjugates Purified from Serum Using Automated Affinity Purification, LC/MS analysis, and Novel DAR Calculation Software

Version 1

    Application Note



    Antibody-drug conjugates (ADCs) are an emerging class of biotherapeutics designed to provide targeted drug delivery by linking drugs to monoclonal antibodies. Unlike small molecule drugs, ADCs are not single molecular entities, but are instead a heterogeneous population of antibodies that vary by the number of drugs on each antibody and by variability in post-translational modifications. The drug-to-antibody ratio (DAR) is the average number of drugs coupled to an ADC. The DAR is a critical quality attribute of an ADC that is optimized and closely monitored during ADC development, as it can affect efficacy and toxicity


    Publication number: 5991-6621EN

    Publication Date: March 30, 2016